EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Risk of gastrointestinal rebleeding in direct oral anticoagulant-treated population

Bianca Codrina Morarasu, Victorita Sorodoc, Constantin Simiras, Stefan Morarasu, Catalina Lionte, Raluca Ecaterina Haliga, Cristina Bologa, Mihai Constantin, Alexandr Ceasovschih, Alexandra-Diana Diaconu, Raluca Elena Alexa, Andreea Asaftei und 3 weitere

Postgraduate Medical Journal · 2025

DOI: 10.1093/postmj/qgaf090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Postgraduate Medical Journal, 2025. Verfasst von Bianca Codrina Morarasu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, Universitatii 16, 700111 Iasi, Romania. Hauptthemen laut MEDLINE: Gastrointestinal Hemorrhage, Anticoagulants. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We performed a retrospective analysis of rebleeding events and their association with direct oral anticoagulant (DOAC) discontinuation versus resumption in patients admitted with an index episode of gastrointestinal bleeding (GIB) while on oral anticoagulants. Materials and methods We included patients ≥18 years between January 2018 and December 2022. The cohort was divided into two groups, initially based on anticoagulant management at discharge, subsequently, according to bleeding events during follow-up, which ended at the time of death, last clinical contact, time of the event, or within 6 months since last patient was included.

Results

A total of 120 patients were included. Those with HAS-BLED score > 3 were more likely discontinue DOAC (P = 0.0009). Significantly more patients with previous GIB had a rebleeding episode (29.6% vs. 6.4%, P = 0.002) and a 4-fold higher risk of rebleeding in the first 15.2 months (HR 4.070, CI [1.771–9.354], P = 0.001). A history of diabetes mellitus, malignancy, CHA2DS2-VASc, and HAS-BLED score > 3 was associated with an increased rebleeding risk, but without statistical significance.

Conclusion

Previous episode of GIB is the most significant risk factor for recurrent bleeding in DOAC-treated patients. It leads to a four times higher risk of bleeding, particularly in the first 15 months. Patients aged ≥75, with a history of diabetes mellitus, malignancy, and HAS-BLED score > 3 should be closely followed-up. Timing of anticoagulation resumption and specific DOAC agent did not influence the rate of rebleeding, supporting their proven benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal HemorrhageAnticoagulantsHumansMaleFemaleRetrospective StudiesAgedRecurrenceRisk FactorsAdministration, OralMiddle AgedAged, 80 and overRisk Assessment

Stichwörter der Autor:innen

anticoagulationbleeding disorders and coagulopathiescardiologyendoscopypharmacology

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, Universitatii 16, 700111 Iasi, Romania.
  • Department of Internal Medicine and Toxicology, Saint Spiridon University Regional Emergency Hospital, Bulevardul Independentei 1, 700111 Iasi, Romania.
  • Department of Gastroenterology, Saint Spiridon University Regional Emergency Hospital, Bulevardul Independentei 1, 700111 Iasi, Romania.
  • 2nd Department of Surgical Oncology, Regional Institute of Oncology (IRO), General Henry Mathias Berthelot 2, 700483, Iasi, Romania.
  • Department of Radiology, Emergency Hospital "Prof. Dr. N. Oblu", Ateneului 2, 700309 Iasi Romania.
  • Department of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Broomhill, Glossop Rd, Sheffield S10 2JF, United Kingdom.

Zitieren

APA

Morarasu, B. C., Sorodoc, V., Simiras, C., Morarasu, S., Lionte, C., Haliga, R. E., Bologa, C., Constantin, M., Ceasovschih, A., Diaconu, A. D., Alexa, R. E., Asaftei, A., Marciuc, E. A., Elsiddig, M., & Sorodoc, L. (2025). Risk of gastrointestinal rebleeding in direct oral anticoagulant-treated population. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgaf090

Vancouver

Morarasu BC, Sorodoc V, Simiras C, Morarasu S, Lionte C, Haliga RE, et al. Risk of gastrointestinal rebleeding in direct oral anticoagulant-treated population. Postgraduate Medical Journal. 2025. doi:10.1093/postmj/qgaf090

BibTeX
@article{Morarasu2025,
  author = {Morarasu, Bianca Codrina and Sorodoc, Victorita and Simiras, Constantin and Morarasu, Stefan and Lionte, Catalina and Haliga, Raluca Ecaterina and Bologa, Cristina and Constantin, Mihai and Ceasovschih, Alexandr and Diaconu, Alexandra-Diana and Alexa, Raluca Elena and Asaftei, Andreea and Marciuc, Emilia Adriana and Elsiddig, Mohammed and Sorodoc, Laurentiu},
  title = {Risk of gastrointestinal rebleeding in direct oral anticoagulant-treated population},
  journal = {Postgraduate Medical Journal},
  year = {2025},
  doi = {10.1093/postmj/qgaf090}
}
Kostenlos starten →